Stem Cell Therapies – Pipeline Insights, 2018

SKU: DM953 | Last Updated On: Aug 11 2022 | Available Formats

The “Stem cell therapies – Pipeline Insights 2018″ report covers the in-depth analysis of Stem cell therapy drug molecules currently undergoing clinical studies.

Stem Cell Therapies

  • Stem cells are used in the replenishment of blood and immune systems. Apart from their use in the immuno-reconstitution, the stem cells have been reported to contribute in the tissue regeneration and as delivery vehicles in the cancer treatments.
  • Stem cells are progenitor cells that are unique in that they are unclassified cells that can modify to become virtually any kind of cell in the body (totipotent).
  • Because of the potential that stem cells can replace defective or damaged cells resulting from a variety of disorders and injuries, an increased focus is noticed leading to a range of new regenerative therapies.
  • Today, we can extract, artificially grow, and transplant them into the body to treat neurodegenerative and autoimmune disorders.
  • Prevailing pipeline candidates for cardiovascular indications are in preclinical development, with ~73% of stem cell pipeline therapies explicitly targeting cardiovascular indications.
  • Currently, there is a lack of big pharma investment in the application of stem cell therapy to cardiovascular clinical development, small biotech companies have undertaken most of the R&D efforts in this space.
  • Introduction of mesenchymal stem cells therapy is presaged as one of the most promising investigational approaches by the market research analysts.
  • The placental stem cells field is projected to grow at the exponential rate; owing to the global mount in the number of placental and cord banks conjugated with growing public awareness.
  • The surge in neurodegenerative diseases and massive investments in adult stem cell research are factors that are contributing to the market growth.
  • Most studies are in clinical phase trials, among which more percentage of studies are under early phase, phase1, phase 2 compared to phase 3 trails. NLA-101 of Nohla, MGTA-456 of Magenta Therapeutics are under phase 2 stage of development.
  • Gamida’s stem cell therapies are in late-stage of development raising expectations on the therapies to be available to patients in the foreseeable future.
  • Factors like public awareness affiliated to the therapeutic potential of stem cells; development of latest technologies for stem cell preservation, processing, and storage; increasing number of stem cell-based research and rising number of hematopoietic stem cell transplantations have led to the market growth of stem cell banking.
  • However, the high operational costs associated with, and stringent regulatory frameworks are expected to restrain the growth of the market.
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest